Skip to main content

Table 1 The equilibrium test of training set and testing set

From: A prediction model for xerostomia in locoregionally advanced nasopharyngeal carcinoma patients receiving radical radiotherapy

Variable

Total (n = 365)

Group

Statistical magnitude

P

Training set (n = 255)

Testing set (n = 110)

Age receiving radiotherapy, Mean ± SD

47.69 ± 11.01

47.97 ± 10.83

47.03 ± 11.44

t = − 0.750

0.452

Gender, n (%)

   

χ2 = 0.089

0.765

 Female

99 (27.12)

68 (26.67)

31 (28.18)

  

 Male

266 (72.88)

187 (73.33)

79 (71.82)

  

History of drinking, n (%)

   

χ2 = 3.079

0.079

 No

322 (88.22)

220 (86.27)

102 (92.73)

  

 Yes

43 (11.78)

35 (13.73)

8 (7.27)

  

History of smoking, n (%)

   

χ2 = 4.120

0.042

 No

273 (74.79)

183 (71.76)

90 (81.82)

  

 Yes

92 (25.21)

72 (28.24)

20 (18.18)

  

History of surgery, n (%)

   

χ2 = 0.213

0.644

 No

307 (84.11)

213 (83.53)

94 (85.45)

  

 Yes

58 (15.89)

42 (16.47)

16 (14.55)

  

History of hypertension, n (%)

   

χ2 = 0.194

0.660

 No

329 (90.14)

231 (90.59)

98 (89.09)

  

 Yes

36 (9.86)

24 (9.41)

12 (10.91)

  

History of diabetes, n (%)

   

1.000

 No

359 (98.36)

251 (98.43)

108 (98.18)

  

 Yes

6 (1.64)

4 (1.57)

2 (1.82)

  

T Stage, n (%)

   

χ2 = 1.056

0.788

 T1

75 (20.55)

50 (19.61)

25 (22.73)

  

 T2

72 (19.73)

53 (20.78)

19 (17.27)

  

 T3

163 (44.66)

115 (45.10)

48 (43.64)

  

 T4

55 (15.07)

37 (14.51)

18 (16.36)

  

N Stage, n (%)

   

χ2 = 2.391

0.495

 N0

35 (9.59)

23 (9.02)

12 (10.91)

  

 N1

147 (40.27)

105 (41.18)

42 (38.18)

  

 N2

153 (41.92)

103 (40.39)

50 (45.45)

  

 N3

30 (8.22)

24 (9.41)

6 (5.45)

  

Pathological type, n (%)

   

χ2 = 1.056

0.304

 A differentiated non-keratinic carcinoma

24 (6.58)

19 (7.45)

5 (4.55)

  

 An undifferentiated nonkeratinic carcinoma

341 (93.42)

236 (92.55)

105 (95.45)

  

Radiotherapy fraction, n (%)

   

χ2 = 0.731

0.393

 ≤ 30

237 (64.93)

162 (63.53)

75 (68.18)

  

 > 30

128 (35.07)

93 (36.47)

35 (31.82)

  

Dose at 50% of the left parotid volume (Gy), Mean ± SD

25.45 ± 7.26

25.56 ± 7.21

25.21 ± 7.41

t = − 0.41

0.681

Dose at 50% of the right parotid volume (Gy), Mean ± SD

25.81 ± 7.72

26.15 ± 8.11

25.03 ± 6.69

t = − 1.37

0.171

Mean dose to left parotid gland (Gy), Mean ± SD

30.99 ± 5.66

31.13 ± 5.68

30.69 ± 5.65

t = − 0.68

0.495

Mean dose to right parotid gland (Gy), Mean ± SD

31.08 ± 6.08

31.38 ± 6.38

30.39 ± 5.26

t = − 1.53

0.127

Mean dose to oral cavity mean dose (Gy), Mean ± SD

32.65 ± 4.68

32.67 ± 4.71

32.59 ± 4.65

t = − 0.150

0.880

Total radiotherapy dose (Gy), n (%)

   

χ2 = 0.452

0.501

 ≤ 70GY

277 (75.89)

191 (74.90)

86 (78.18)

  

 > 70GY

88 (24.11)

64 (25.10)

24 (21.82)

  

Mode of radiotherapy-NDP, n (%)

   

χ2 = 0.428

0.513

 No

173 (47.40)

118 (46.27)

55 (50.00)

  

 Yes

192 (52.60)

137 (53.73)

55 (50.00)

  

Mode of radiotherapy-DDP, n (%)

   

χ2 = 0.782

0.377

 No

286 (78.36)

203 (79.61)

83 (75.45)

  

 Yes

79 (21.64)

52 (20.39)

27 (24.55)

  

Mode of radiotherapy-Others, n (%)

   

χ2 = 0.000

0.989

 No

345 (94.52)

241 (94.51)

104 (94.55)

  

 Yes

20 (5.48)

14 (5.49)

6 (5.45)

  

Course of induction chemotherapy, M (Q1, Q3)

2.00 (2.00, 3.00)

2.00 (2.00, 3.00)

2.00 (2.00, 3.00)

Z = 0.040

0.968

Concomitant chemoradiotherapy, n (%)

   

χ2 = 0.049

0.824

 No

77 (21.10)

53 (20.78)

24 (21.82)

  

 Yes

288 (78.90)

202 (79.22)

86 (78.18)

  

Induction chemotherapy, n (%)

   

χ2 = 0.000

0.986

 No

30 (8.22)

21 (8.24)

9 (8.18)

  

 Yes

335 (91.78)

234 (91.76)

101 (91.82)

  

The regimens of induction chemotherapy, n (%)

   

χ2 = 2.252

0.895

 DP

111 (30.41)

79 (30.98)

32 (29.09)

  

 DPF

55 (15.07)

35 (13.73)

20 (18.18)

  

 GP

59 (16.16)

43 (16.86)

16 (14.55)

  

 None

30 (8.22)

21 (8.24)

9 (8.18)

  

 Others

4 (1.10)

2 (0.78)

2 (1.82)

  

 TP

65 (17.81)

47 (18.43)

18 (16.36)

  

 TPF

41 (11.23)

28 (10.98)

13 (11.82)

  

Xerostomia, n (%)

   

χ2 = 1.990

0.574

 Grade 0

84 (23.01)

63 (24.71)

21 (19.09)

  

 Grade 1

142 (38.90)

94 (36.86)

48 (43.64)

  

 Grade 2

108 (29.59)

76 (29.80)

32 (29.09)

  

 Grade 3

31 (8.49)

22 (8.63)

9 (8.18)

  
  1. PFS progression-free survival, NDP Nedaplatin, DDP cisplatin, DPF docetaxel + cisplatin + 5-fluorouracil, TPF docetaxel + cisplatin + 5-fluorouracil, DP cisplatin + docetaxel, TP cisplatin, GP gemcitabine + cisplatin, SD standard deviation